Equities Analysts Set Expectations for FDMT FY2025 Earnings

Key Points

• Analysts at Leerink Partners have adjusted their FY2025 earnings per share (EPS) estimate for 4D Molecular Therapeutics to ($3.69), slightly up from a previous estimate of ($3.82).
• The company's recent earnings report showed a loss of ($0.98) EPS for the quarter, which was below the consensus estimate of ($0.88) EPS.
• 4D Molecular Therapeutics has received a range of ratings from analysts, with a consensus rating of "Moderate Buy" and an average price target of $30.40.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a research note issued on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($3.69) per share for the year, up from their prior estimate of ($3.82). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics' Q4 2025 earnings at ($0.81) EPS and FY2026 earnings at ($3.73) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million.

Other equities research analysts have also issued reports about the stock. Roth Capital lowered their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Finally, Chardan Capital reiterated a "buy" rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $30.40.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $10.09 on Friday. 4D Molecular Therapeutics has a one year low of $2.23 and a one year high of $10.73. The firm has a market cap of $471.20 million, a price-to-earnings ratio of -2.86 and a beta of 2.93. The firm's fifty day moving average is $7.48 and its two-hundred day moving average is $5.08.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd purchased a new position in 4D Molecular Therapeutics in the 1st quarter valued at about $39,000. Y Intercept Hong Kong Ltd purchased a new position in 4D Molecular Therapeutics in the 1st quarter valued at about $41,000. Los Angeles Capital Management LLC purchased a new position in 4D Molecular Therapeutics in the 2nd quarter valued at about $42,000. Quadrature Capital Ltd purchased a new position in 4D Molecular Therapeutics in the 2nd quarter valued at about $42,000. Finally, Farther Finance Advisors LLC lifted its stake in 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock valued at $43,000 after buying an additional 2,674 shares in the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.